Amgen (NASDAQ: AMGN) Stock Analysis: RBC Capital Raises Price Target Amidst Strong Performance and Upcoming Earnings

• RBC Capital has increased its price target for Amgen, signaling analyst confidence in the biotechnology stock.
• Amgen's stock has recently shown strong performance, outperforming broader market indices and its sector.
• Investors anticipate positive growth in Amgen's upcoming quarterly earnings per share and revenue figures.

Amgen (NASDAQ: AMGN) is a biotechnology company that develops medicines for serious illnesses. RBC Capital raises its price target for the stock to $430.00 from $400.00. Shares trade near $407.58 at the time of the announcement, putting the new target about 5.5% above the share price. A price target is an analyst’s estimate, not a guaranteed return.

The higher target comes as the stock shows strength in one recent trading update. As highlighted by Zacks, Amgen rises 2.6% to close at $413.08 on October 7, while the S&P 500 falls 0.22%. In that update, Amgen gains 2.4% over the past month, compared with a 4.73% decline in the Medical sector.

Investors also have an upcoming earnings report to consider. Analysts expect quarterly earnings of $5.69 per share, up 0.89% from a year earlier, and revenue of $9.91 billion, up 3.68%. Earnings per share measure profit divided by the number of shares; revenue is the money the company brings in before expenses.

Other figures reflect different points in time. As highlighted by Zacks, one update shows Amgen down 7.8% over a month, while its biomedical and genetics industry falls 6.7%. A separate price snapshot puts Amgen at $404.72, down 2.02% for the day and below RBC Capital’s $430.00 target.